|
2024
|
Invention
|
Morphic forms of trilaciclib and methods of manufacture thereof.
An advantageous isolated morphi... |
|
2023
|
Invention
|
Combination treatments in difficult to treat patients with advanced and/or metastatic trop-2 over... |
|
|
Invention
|
Transient protection of normal cells during chemotherapy.
This invention is in the area of impro... |
|
|
Invention
|
Cdk inhibitors.
Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereo... |
|
|
Invention
|
Hspc-sparing treatments for rb-positive abnormal cellular proliferation.
This invention is in th... |
|
2022
|
Invention
|
Preservation of immune response during chemotherapy regimens.
The addition of a selective, fast-... |
|
|
Invention
|
Highly active anti-neoplastic and anti-proliferative agents.
This invention is in the area of im... |
|
|
Invention
|
Treatment of egfr-driven cancer with fewer side effects.
The present invention provides methods ... |
|
|
Invention
|
G1t38 superior dosage regimes.
A G1T38 human oral dosage regime that provides a (mean AUC(0-24),... |
|
|
Invention
|
Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]tria... |
|
|
Invention
|
Targeted treatment of cancers with dysregulated fibroblast growth factor receptor signaling.
The... |
|
|
Invention
|
Morphic forms of g1t38 and methods of manufacture thereof. This invention provides an unexpectedl... |
|
2021
|
Invention
|
Patient selection for enhancement of anti-tumor immunity in cancer patients.
A method for increa... |
|
|
Invention
|
Morphic forms of trilaciclib and methods of manufacture thereof. An advantageous isolated morphic... |
|
|
Invention
|
Transient protection of normal cells during chemotherapy. This invention is in the area of improv... |
|
|
Invention
|
Synthesis of 1,4-diazaspiro[5.5]undecan-3-one. This invention provides a process for preparing 1,... |
|
|
Invention
|
Hspc-sparing treatments for rb-positive abnormal cellular proliferation. This invention is in the... |
|
2020
|
Invention
|
Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines. This invention is in the area of sy... |
|
|
Invention
|
G1t38 superior dosage regimes. A G1T38 human oral dosage regime that provides a (mean AUC(0-24),s... |
|
|
Invention
|
Cdk inhibitors. Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof... |
|
|
Invention
|
Benzothiophene estrogen receptor modulators. This invention is a benzothiophene estrogen receptor... |
|
2019
|
Invention
|
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin depende... |
|
|
Invention
|
Treatment of egfr-driven cancer with fewer side effects. The present invention provides methods f... |
|
|
Invention
|
Combination therapy for treatment of cancer. Compositions, combinations and methods comprising a ... |
|
|
Invention
|
Preservation of immune response during chemotherapy regimens. The addition of a selective, fast-a... |
|
|
Invention
|
Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor compounds to treat rb-pos... |
|
2018
|
Invention
|
Antiproliferative pyrimidine-based compounds. This invention is in the area of pyrimidine-based c... |
|
|
Invention
|
Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents. T... |
|
|
Invention
|
Pyrimidine-based compounds for the treatment of cancer. This invention is in the area of pyrimidi... |
|
|
Invention
|
Highly active anti-neoplastic and anti-proliferative agents. This invention is in the area of imp... |
|
|
Invention
|
Cdk inhibitors. Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof... |
|
|
Invention
|
Treatment of rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors. ... |
|
|
Invention
|
Lactam kinase inhibitors. Compounds useful as kinase inhibitors are provided herein, as well as s... |
|
2017
|
Invention
|
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferat... |
